Back to search

Article

Phase II Trial of Veliparib and Temozolomide in Metastatic Breast Cancer Patients With and Without BRCA1/2mutations

2021-02-25

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose: </bold>We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline <italic>BRCA1/2</italic> mutations.<bold>Methods: </bold>In this single-arm phase II trial, patients with metastatic breast cancer received veliparib 30 to 40 mg twi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2eb26a99-27de-534f-998f-37ab669c8c0f
DOI
10.21203/rs.3.rs-268461/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Phase II Trial of Veliparib and Temozolomide in Metastatic Breast Cancer Patients With and Without BRCA1/2mutationsDOI 10.21203/rs.3.rs-268461/v1
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.Semantic proximity
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.Semantic proximity
An Open Label, Pilot Study of Veliparib and Lapatinib in Patients with Metastatic, Triple Negative Breast CancerSemantic proximity
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.Semantic proximity
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group studySemantic proximity
An Overview of PARP Inhibitors for the Treatment of Breast CancerSemantic proximity
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.Semantic proximity
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.Semantic proximity
Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancerSemantic proximity
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid TumorsSemantic proximity
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.Semantic proximity
BRCA1/2 testing: therapeutic implications for breast cancer managementSemantic proximity
Select a neighboring publication to make it the new centre.